



Business Update @ Dalal & Broacha


BUY

Current Price	301
Target Price	369
Upside/Downside	23%
52 Week Range	211/323

Key Share Data

Market Cap (Rs.bn)	360
Market Cap (US\$ Bn)	4.96
No of o/s shares (mn)	1200
Face Value	5
Monthly Avg.vol (BSE+NSE) Nos'000	5054
BSE Code	532523
NSE Code	BIOCON
Bloomberg	BIOS:IN

Price performance



% Shareholding	Dec -19	Sept-19
Promoters	60.67	60.67
FII	16.09	15.75
DII	6.75	4.85
Others	16.49	18.73
Total	100	100

Key Financials

Year	Net sales	% Growth	EBIDTA	OPM (%)	PAT ex EI	PAT incl EI	% Growth	EPS*	PE (x)	EV/EBITDA	RoE (%)	RoCE (%)
FY18	41,297.0	5.3	8,354.0	20.2	3,787.0	3,787.0	(39.2)	6.3	47.7	44.6	8.5	5.6
FY19	55,144.0	33.5	13,937.0	25.3	7,107.0	9,053.0	90.8	11.8	25.4	27.2	13.2	11.8
FY20E	68,381.5	24.0	17,753.0	26.0	8,875.5	9,550.5	24.9	7.4	40.7	21.1	12.7	11.3
FY21E	86,820.5	27.0	23,129.2	26.6	12,330.5	12,330.5	38.9	10.3	29.3	16.6	16.4	13.8
FY22E	107,706.9	24.1	30,239.1	28.1	17,094.1	17,094.1	38.6	14.2	21.1	12.7	19.1	16.6

*Adjusted for bonus in the proportion of 2:1 in FY18 and 1:1 in FY20

The patent win for Mylan's 505 (b)(2) NDA filing for SEMGLEE (biosimilar to Glargine) Vs Sanofi Inc, are a step forward to provide affordable insulin to the US. The product is currently under active review by the USFDA, with 3 observations to Biocon's Malaysia plant.

We believe Biocon has emerged as a global player in research & development and operational efficiencies for biosimilars. The management is confident of achieving biologics revenue of \$ 1 bn by FY22, through an improvement in market share in biosimilars in the US, EU and Emerging markets.

We maintain our BUY rating on Biocon.

Mylan's patent win for Glargine

- The US District Court of New Jersey has found that the device patent claims asserted by Sanofi for SOLOSTAR against Mylan's insulin GLARGINE, do not infringe Sanofi's patents and are invalid for lack of written description.
 - The Federal Circuit has previously affirmed Sanofi's patents '652 and '930 as invalid.
 - The judgement is a step forward for patient access and Mylan's effort towards affordable insulin Glargine, which is currently under active USFDA review.
 - LANTUS is long acting insulin to treat adults with type 1 diabetes, available in vials and pen (Lantus SOLOSTAR). Revenues (TTM Jan'20) were at \$1.73 bn for LANTUS and \$4.24 bn for LANTUS SOLOSTAR.
- The USFDA has issued 3 observations to Biocon's Malaysia plant. Biocon is in the process of responding to the USFDA and is confident of addressing the procedural issues. Mylan believes that the inspection will not hamper the commercialisation plans for Glargine.
- Mylan+ Biocon have filed the biosimilar for AVASTIN (Bevacizumab) with the USFDA. The USFDA has issued a user fee goal date of December 27, 2020 for the same. AVASTIN (innovator Genentech (Roche) clocked global sales of CHF 5.5 bn for 9MCY2019 (USD 5.7 bn), of which \$ 2.5 bn are from the US. **Annually, the global market size for Bevacizumab would be \$7 bn. Bevacizumab will be the third oncology biosimilar from Mylan+ Biocon.**

Valuation

At CMP, Biocon trades at 21x FY22E EPS of Rs 14.2, and 13x FY22E EV/EBITDA.

We maintain our BUY rating on Biocon with a target price of Rs 369.


DALAL & BROACHA
 STOCK BROKING PVT. LTD.

Business update@ Dalal & Broacha

P&L (Rs mn)	BIOCON FINANCIALS					Cash Flow St. (Rs. mn)	FY18	FY19	FY20E	FY21E	FY22E
	FY18	FY19	FY20E	FY21E	FY22E						
Net Sales	41,297.0	55,144.0	68,381.5	86,820.5	107,706.9	Net Profit	3,724.0	9,053.0	9,550.5	12,330.5	17,094.1
Raw materials	(16,361.0)	(18,966.0)	(21,882.1)	(28,650.8)	(35,543.3)	Add: Dep. & Amort.	3,851.0	4,478.0	4,941.2	5,341.1	5,941.1
Employee costs	(9,311.0)	(11,653.0)	(14,566.3)	(18,207.8)	(22,759.8)	Cash profits	7,575.0	13,531.0	14,491.8	17,671.7	23,035.3
Other Expenses	(5,111.0)	(7,688.0)	(10,378.8)	(12,973.5)	(14,919.5)	(Inc)/Dec in					
Research & Devt	(2,160.0)	(2,900.0)	(3,801.4)	(3,859.3)	(4,245.3)	-Sundry debtors	(1,807.0)	(2,279.0)	(2,069.7)	(4,041.4)	(4,577.8)
Cost of sales	(32,943.0)	(41,207.0)	(50,628.5)	(63,691.3)	(77,467.8)	-Inventories	(872.0)	(3,091.0)	(2,067.3)	(3,293.9)	(3,730.3)
Operating Profit	8,354.0	13,937.0	17,753.0	23,129.2	30,239.1	-Loans/advances	224.0	(1,475.0)	(1,148.4)	(1,378.1)	(1,653.7)
Depreciation	(3,851.0)	(4,478.0)	(4,941.2)	(5,341.1)	(5,941.1)	-Sundry creditors	2,656.0	1,930.0	729.1	3,932.2	4,004.1
PBIT	4,503.0	9,459.0	12,811.8	17,788.0	24,297.9	-Others	(3,665.0)	1,714.0	1,377.2	1,652.6	1,983.2
Other income	2,062.0	1,444.0	1,155.2	1,213.0	1,273.6	Change in WC	(3,464.0)	(3,201.0)	(3,179.1)	(3,128.6)	(3,974.6)
Interest	(615.0)	(709.0)	(894.6)	(1,007.8)	(1,073.4)	CF from Oper. activities	4,111.0	10,330.0	11,312.6	14,543.0	19,060.7
Profit before tax	5,950.0	10,194.0	13,072.4	17,993.2	24,498.2	CF from Inv. activities	(8,485.0)	(12,263.0)	(12,360.8)	(11,967.0)	(15,850.6)
Provision for tax	(1,569.0)	(2,123.0)	(3,137.4)	(4,498.3)	(6,124.5)	CF from Fin. activities	8,036.0	961.0	4,800.2	(2,036.8)	(1,673.0)
Profit after Tax	4,381.0	8,071.0	9,935.0	13,494.9	18,373.6	Cash generated/(utilised)	3,662.0	(972.0)	3,752.0	539.3	1,537.1
Minority Interest	(807.0)	(973.0)	(1,070.3)	(1,177.3)	(1,295.1)	Cash at start of the year	10,443.0	13,395.0	10,572.0	19,041.2	13,513.5
Share of Profit	213.0	9.0	10.8	13.0	15.6	Cash at end of the year	13,395.0	10,572.0	19,041.2	13,513.5	-
Adjusted PAT	3,787.0	7,107.0	8,875.5	12,330.5	17,094.1	Ratios	FY18	FY19	FY20E	FY21E	FY22E
Extraordinary Items	-	1,946.0	675.0	-	-	OPM	20.2	25.3	26.0	26.6	28.1
Reported PAT	3,787.0	9,053.0	9,550.5	12,330.5	17,094.1	NPM	8.7	16.0	13.7	14.0	15.7
Balance Sheet	FY18	FY19	FY20E	FY21E	FY22E	Tax rate	(26.4)	(20.8)	(24.0)	(25.0)	(25.0)
Equity capital *	3,000.0	3,000.0	6,000.0	6,000.0	6,000.0	Growth Ratios (%)					
Reserves	48,808.0	57,980.0	72,250.5	76,221.1	90,315.2	Net Sales	5.3	33.5	24.0	27.0	24.1
Net worth	51,808.0	60,980.0	78,250.5	82,221.1	96,315.2	Operating Profit	(15.4)	68.1	27.4	30.3	30.7
Def. Tax Liab.+Minority Int.	4,677.0	6,089.0	6,697.9	7,367.7	8,104.5	PAT excl. EI	(39.2)	90.8	24.9	38.9	38.6
Secured loans	17,898.0	15,256.0	18,944.7	22,200.3	22,239.1	Per Share (Rs.)*					
Unsecured loans	1,303.0	2,612.0	2,274.0	2,275.0	2,276.0	Adj. Net Earnings (EPS)	6.3	11.8	7.4	10.3	14.2
Current Maturities	5,730.0	10,066.0	10,484.0	11,008.2	11,558.6	Cash Earnings (CPS)	12.7	22.6	12.1	14.7	19.2
Total debt	24,931.0	27,934.0	31,702.7	35,483.5	36,073.7	Dividend	5.0	5.0	6.0	6.0	7.0
Other liab	3,423.0	8,052.0	9,662.4	11,594.9	13,913.9	Book Value	86.3	101.6	65.2	68.5	80.3
CAPITAL EMPLOYED	84,839.0	103,055.0	126,313.5	136,667.1	154,407.2	Free Cash Flow	(7.3)	(3.2)	(0.9)	2.1	2.7
Gross block	57,532.0	68,019.0	76,019.0	89,019.0	99,019.0	Valuation Ratios					
Accumulated depreciation	(21,591.0)	(26,069.0)	(31,010.2)	(36,351.4)	(42,292.5)	P/E(x)	47.7	25.4	40.7	29.3	21.1
Net block	36,297.0	42,527.0	45,008.8	52,667.6	56,726.5	P/B(x)	3.5	3.0	4.6	4.4	3.7
Capital WIP	7,789.0	12,869.0	17,339.0	17,339.0	17,339.0	EV/EBIDTA(x)	44.6	27.2	21.1	16.6	12.7
Total fixed assets	44,086.0	55,396.0	62,347.8	70,006.6	74,065.5	EV/SALES (x)	9.0	6.9	5.5	4.4	3.6
Intangible Assets	5,937.0	8,303.0	9,955.0	10,343.0	10,343.0	Div. Yield(%)	1.7	1.7	2.0	2.0	2.3
Investments	6,752.0	10,118.0	12,055.4	15,542.7	23,098.6	FCF Yield(%)	(2.4)	(1.1)	(0.3)	0.7	0.9
Other non current assets	3,186.0	2,131.0	2,557.2	3,068.6	3,682.4	Return Ratios (%)					
Inventories	7,225.0	10,316.0	12,383.3	15,677.2	19,407.5	ROE	8.5	13.2	12.7	16.4	19.1
Sundry debtors	10,639.0	12,918.0	14,987.7	19,029.1	23,607.0	ROCE	5.6	11.8	11.3	13.8	16.6
Cash & bank	13,395.0	10,572.0	19,041.2	13,513.5	14,272.8						
Loans & advances	4,267.0	5,742.0	6,890.4	8,268.5	9,922.2						
Other current assets	1,370.0	1,488.0	1,636.8	1,800.5	1,980.5						
Sundry creditors	(10,053.0)	(11,983.0)	(12,712.1)	(16,644.2)	(20,648.3)						
Acceptances	(4,214.0)	(5,420.0)	(6,504.0)	(7,804.8)	(9,365.8)						
Provisions	(958.0)	(1,466.0)	(1,759.2)	(2,111.0)	(2,533.2)						
Working capital	24,878.0	27,107.0	39,398.2	37,706.1	43,217.8						
CAPITAL DEPLOYED	84,839.0	103,055.0	126,313.5	136,667.1	154,407.2						

* Increase in Equity on account of bonus issue in FY17 (2:1) and FY19 in the proportion of 1:1



DALAL & BROACHA
STOCK BROKING PVT. LTD.

Business update@ Dalal & Broacha

Disclaimer

Dalal & Broacha Stock Broking Pvt Ltd, hereinafter referred to as D& B (CIN_U67120MH1997PTC111186) was established in 1997 and is an integrated financial services player offering an extensive range of financial solutions and services to a wide spectrum of customers with varied needs ranging from equities to mutual funds to depository services.

D&B is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE). D&B along with its affiliates offers the most comprehensive avenues for investments and is engaged in the securities businesses including stock broking (Institutional and retail), depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.dalal-broacha.com

D&B is registered as Research Analyst with SEBI bearing registration Number INH000001246 as per SEBI (Research Analysts) Regulations, 2014.

D&B hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in any time in the past. It has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on D&B for certain operational deviations in routine course of business.

D&B offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by D&B (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

D&B or its associates may have financial interest in the subject company.

D&B or its associates do not have any material conflict of interest in the subject company.

The Research Analyst or Research Entity (D&B) has not been engaged in market making activity for the subject company.

D&B or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

Disclosures in respect of Research Analyst:

Whether Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report:	No
Whether the Research Analyst or his/her relative's financial interest in the subject company.	No
Whether the research Analyst has served as officer, director or employee of the subject company	No
Whether the Research Analyst has received any compensation from the subject company in the past twelve months	No
Whether the Research Analyst has managed or co-managed public offering of securities for the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for investment banking or	No



DALAL & BROACHA
STOCK BROKING PVT. LTD.

Business update@ Dalal & Broacha

merchant banking or brokerage services from the subject company in the past twelve months	
Whether the Research Analyst has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation or other benefits from the subject company or third party in connection with the research report	No

D&B and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject D&B or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to D&B. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of D&B. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of D&B or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Contact	Email ID	Contact No.	Sector
Mr. Kunal Bhatia	kunal.bhatia@dalal-broacha.com	022 67141442	Auto, Auto Ancillary, FMCG
Ms.Charulata Gaidhani	charulata.gaidhani@dalal-broacha.com	022 67141446	Pharma /Healthcare
Ms. Abhilasha Satale	abhilasha.satale@dalal-broacha.com	022 67141439	Midcaps
Mr. Mayank Babla	Mayank.babla@dalal-broacha.com	022 67141412	I.T
Mr. Avinash Tanawade	Avinash.tanawade@dalal-broacha.com	022 67141449	Banking & Finance
Mr. Suraj Nandu	suraj.nandu@dalal-broacha.com	022 67141438	Associate
Ms. Nidhi Babaria	Nidhi.babaria@dalal-broacha.com	022 67141450	Associate
Mr. Tanush Mehta	tanush.mehta@dalal-broacha.com	022 67141432	Associate



DALAL & BROACHA
STOCK BROKING PVT. LTD.

Business update@ Dalal & Broacha

Address: - 508, Maker Chambers V, 221 Nariman Point, Mumbai 400 021 Tel: 91-22- 2282 2992, 2287 6173 Fax: 91-22-2287 0092 E-mail:, equity.research@dalal-broacha.com